ProKidney Corp.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.69
- Today's High:
- $8.56
- Open Price:
- $8.35
- 52W Low:
- $5.14
- 52W High:
- $14.19
- Prev. Close:
- $8.35
- Volume:
- 457668
Company Statistics
- Market Cap.:
- $2.03 billion
- Book Value:
- -21.469
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.03%
- Return on Equity TTM:
- -56.21%
Company Profile
ProKidney Corp. had its IPO on 2022-07-12 under the ticker symbol PROK.
The company operates in the Healthcare sector and Biotechnology industry. ProKidney Corp. has a staff strength of 87 employees.
Stock update
Shares of ProKidney Corp. opened at $8.35 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.69 - $8.56, and closed at $7.71.
This is a -7.66% slip from the previous day's closing price.
A total volume of 457,668 shares were traded at the close of the day’s session.
In the last one week, shares of ProKidney Corp. have slipped by -10.76%.
ProKidney Corp.'s Key Ratios
ProKidney Corp. has a market cap of $2.03 billion, indicating a price to book ratio of 91.3172 and a price to sales ratio of 0.
In the last 12-months ProKidney Corp.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-143226000. The EBITDA ratio measures ProKidney Corp.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ProKidney Corp.’s operating margin was 0% while its return on assets stood at -34.03% with a return of equity of -56.21%.
In Q2, ProKidney Corp.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ProKidney Corp.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ProKidney Corp.’s profitability.
ProKidney Corp. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.0518. Its price to sales ratio in the trailing 12-months stood at 0.
ProKidney Corp. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $484.22 million
- Total Liabilities
- $24.50 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $3.70 million
- Dividend Payout Ratio
- 0%
ProKidney Corp. ended 2024 with $484.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $484.22 million while shareholder equity stood at $-1322254000.00.
ProKidney Corp. ended 2024 with $0 in deferred long-term liabilities, $24.50 million in other current liabilities, 24000.00 in common stock, $-1353108000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $243.55 million and cash and short-term investments were $446.13 million. The company’s total short-term debt was $654,000 while long-term debt stood at $0.
ProKidney Corp.’s total current assets stands at $466.43 million while long-term investments were $0 and short-term investments were $202.58 million. Its net receivables were $8.09 million compared to accounts payable of $2.83 million and inventory worth $11.61 million.
In 2024, ProKidney Corp.'s operating cash flow was $0 while its capital expenditure stood at $3.70 million.
Comparatively, ProKidney Corp. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.71
- 52-Week High
- $14.19
- 52-Week Low
- $5.14
- Analyst Target Price
- $15.2
ProKidney Corp. stock is currently trading at $7.71 per share. It touched a 52-week high of $14.19 and a 52-week low of $14.19. Analysts tracking the stock have a 12-month average target price of $15.2.
Its 50-day moving average was $10.7 and 200-day moving average was $10.41 The short ratio stood at 43.9 indicating a short percent outstanding of 0%.
Around 2234.3% of the company’s stock are held by insiders while 6535.8% are held by institutions.
Frequently Asked Questions About ProKidney Corp.
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.